[{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"China Life Private Equity Investment","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Series C Financing","leadProduct":"GQ1001","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GeneQuantum Healthcare \/ China Life Private Equity Investment","highestDevelopmentStatusID":"6","companyTruncated":"GeneQuantum Healthcare \/ China Life Private Equity Investment"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"BrighGene Biomedical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"GQ1007","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ BrighGene Biomedical","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantum Healthcare \/ BrighGene Biomedical"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Aimed Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"AMB302","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ Aimed Bio","highestDevelopmentStatusID":"4","companyTruncated":"GeneQuantum Healthcare \/ Aimed Bio"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"GQ1005","moa":"HER2 receptor","graph1":"Oncology","graph2":"IND Enabling","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"GeneQuantum Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Pyramid Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"GQ1010","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"GeneQuantum Healthcare","amount2":1.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":1.02,"dosageForm":"Injectable\/Injection","sponsorNew":"GeneQuantum Healthcare \/ GeneQuantum Healthcare","highestDevelopmentStatusID":"4","companyTruncated":"GeneQuantum Healthcare \/ GeneQuantum Healthcare"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"GeneQuantum Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"CHINA","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"GeneQuantum Healthcare","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ GeneQuantum Healthcare","highestDevelopmentStatusID":"2","companyTruncated":"GeneQuantum Healthcare \/ GeneQuantum Healthcare"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Aimed Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Expanded Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ Aimed Bio","highestDevelopmentStatusID":"2","companyTruncated":"GeneQuantum Healthcare \/ Aimed Bio"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"InxMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ InxMed","highestDevelopmentStatusID":"2","companyTruncated":"GeneQuantum Healthcare \/ InxMed"},{"orgOrder":0,"company":"GeneQuantum Healthcare","sponsor":"Nona Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Bioconjugate","moa":"","graph1":"Technology","graph2":"Discovery","graph3":"GeneQuantum Healthcare","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Technology","amount2New":0,"dosageForm":"","sponsorNew":"GeneQuantum Healthcare \/ Nona Biosciences","highestDevelopmentStatusID":"2","companyTruncated":"GeneQuantum Healthcare \/ Nona Biosciences"}]

Find Clinical Drug Pipeline Developments & Deals by GeneQuantum Healthcare

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Under the collaboration, Nona Biosciences will integrate GeneQuantum's exclusive and innovative iLDC and iGDC platforms, with its Harbour Mice® platform and cutting-edge technologies, to advance the early discovery of next-generation bioconjugates.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          November 13, 2023

                          Lead Product(s) : Bioconjugate

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery

                          Sponsor : Nona Biosciences

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Under the agreement, GeneQuantum will provide InxMed with its globally leading technologies in site-specific glycan conjugation, stable linker small molecule technology, and intelligent continuous conjugation production platform for developing innovative...

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 17, 2023

                          Lead Product(s) : Antibody-drug Conjugate

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : InxMed

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Under the collaboration, GeneQuantum and Aimed Bio aims to jointly develop up to five new antibody-drug conjugate drugs to address unmet clinical needs for patients with severe brain diseases.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 06, 2023

                          Lead Product(s) : Antibody-drug Conjugate

                          Therapeutic Area : Oncology

                          Highest Development Status : Discovery

                          Sponsor : Aimed Bio

                          Deal Size : Undisclosed

                          Deal Type : Expanded Collaboration

                          blank

                          04

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Under the partnership, GQ will leverage TOBio's expertise in CMC and commercial manufacturing to advance its pharmaceutical research on antibody-drug conjugate (ADC) products by using its innovative conjugation technology.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 22, 2023

                          Lead Product(s) : Antibody-drug Conjugate

                          Therapeutic Area : Technology

                          Highest Development Status : Discovery

                          Recipient : Thousand Oaks Biologics

                          Deal Size : $28.3 million

                          Deal Type : Partnership

                          blank

                          05

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Under the terms of the agreement, Pyramid Biosciences will develop and commercialize GQ1010, a potential best-in-class antibody drug conjugate (ADC) targeting TROP2, worldwide except for Greater China, using GeneQuantum's proprietary technology.

                          Brand Name : GQ1010

                          Molecule Type : Large molecule

                          Upfront Cash : $20.0 million

                          April 13, 2023

                          Lead Product(s) : GQ1010

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Recipient : Pyramid Bio

                          Deal Size : $1,020.0 million

                          Deal Type : Licensing Agreement

                          blank

                          06

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : GQ1005, is a HER2 targeting ADC with an excellent bystander killing effect, and the stable linker technology have demonstrated the advantages through several IND enabled drug candidates.

                          Brand Name : GQ1005

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 15, 2022

                          Lead Product(s) : GQ1005

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : The collaborating ADC is a first-in-class asset AMB302, with highly differentiated antibody against a unique target, a stable linker design and a novel payload with a strong by-stander killing effect.

                          Brand Name : AMB302

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          April 19, 2022

                          Lead Product(s) : AMB302

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Aimed Bio

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          08

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : Both companies signed a co-development agreement for antibody immune agonist conjugate (AIAC), GQ1007. GQ1007 is a new type of antibody-drug conjugate which has achieves strong and lasting anti-tumor effect, overcomes the low response rate of PD-1 antibo...

                          Brand Name : GQ1007

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          September 05, 2021

                          Lead Product(s) : GQ1007

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : BrighGene Biomedical

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          09

                          Compamed
                          Not Confirmed
                          Compamed
                          Not Confirmed

                          Details : GQ1001 is an antibody drug conjugate (ADC) that is currently in global multi-center clinical trial development for treatment of HER2+ solid tumor. GQ1001 was synthesized by site-specific conjugation of toxin DM1 to trastuzumab.

                          Brand Name : GQ1001

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          May 19, 2021

                          Lead Product(s) : GQ1001

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : China Life Private Equity Investment

                          Deal Size : Undisclosed

                          Deal Type : Series C Financing

                          blank